Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Top Ranked Income Stocks to Buy for February 22nd

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 22nd

Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

Merck Gets Priority Review for Keytruda in Third-Line SCLC

by Zacks Equity Research

Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.

Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct

by Zacks Equity Research

Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.

Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

by Zacks Equity Research

Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

Nitish Marwah headshot

New Strong Buy Stocks for February 19th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Top Ranked Growth Stocks to Buy for February 15th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 15th

Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

by Zacks Equity Research

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up

by Zacks Equity Research

Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 14th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Top Ranked Income Stocks to Buy for February 14th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 14th

Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

by Zacks Equity Research

Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

by Zacks Equity Research

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

by Zacks Equity Research

Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge

Mark Vickery headshot

Big Q4 Numbers & New Trade Data

by Mark Vickery

Plenty of Q4 earnings numbers join new Manufacturing and Trade data, some of which had been previously delayed due to the government shutdown.

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q4

by Zacks Equity Research

Glaxo beats both earnings and sales estimates in the fourth quarter of 2018.

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

by Zacks Equity Research

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

What's in the Cards for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.

Mylan's Generic Version of Advair Diskus Wins FDA Approval

by Zacks Equity Research

Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

GlaxoSmithKline (GSK) Flat As Market Gains: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.

Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines

by Zacks Equity Research

Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.